Replies to post #124115 on Biotech Values

[NP1986]

There are payor issues as well to consider between IV and oral formulations.

[BTH]

Currently, I am relating this to Curis' CUDC-101, although, yes, Ariad is a good example of this.

[vinmantoo]

What matters for the oral version is to reach a drug level that provides clinical activity. If you can it doesn't really matter if you can reach a higher amount via IV.